Adverse Effects

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Global Bulletin

All News

FDA Approval Alert

Women in Oncology

Media

Expert Interviews

Around the Practice

Between the Lines

Face Off

From All Angles

Meeting of the Minds

OncView

Podcasts

Training Academy

Treatment Algorithms with the Oncology Brothers

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Cancer Network

Facebook

LinkedIn

Spotlight

Clinical

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

IMbrave150: Atezolizumab plus Bevacizumab in HCC: Efficacy Data and Clinical Practice Implications

Video Series

IMbrave 150: Overview

Videos

Rahul Gosain, MD; Rohit Gosain, MD, and Daniel Ahn, DO, analyze pivotal studies in hepatocellular carcinoma, including HIMALAYA, IMbrave 150, and CheckMate 9DW, discussing study designs, outcomes, patient characteristics, and efficacy data.

Medical experts specializing in hepatocellular carcinoma (HCC) provide a detailed analysis of the IMbrave 150 study design.

IMbrave 150: Overview  

The panel analyzes how patient characteristics from the IMbrave 150 trial compare to those in other hepatocellular carcinoma studies.

IMbrave 150: Patient Characteristics

The panel presents the latest safety and efficacy updates from the IMbrave 150 trial.

IMbrave 150: Updated Outcomes

Key opinion leaders share their impressions of the IMBrave150 trial data and discuss their real-world clinical experiences using atezolizumab plus bevacizumab in practice.

Using Atezolizumab + Bevacizumab in Practice

Medical experts analyze the exploratory efficacy and safety results for patients with portal vein invasion (Vp4), addressing the challenges in treating this subgroup.

Vp4 and Baseline Varices Data in IMbrave 150: Clinical Implications

Key opinion leaders examine IMbrave 150 data stratified by baseline varices and compare outcomes between patients with Child-Pugh A and B.

AE Management with Atezolizumab + Bevacizumab

The panel reviews the CheckMate 9DW study design and evaluates its safety data.

CheckMate 9DW: Overview

Key opinion leaders summarize essential takeaways and highlight unmet needs in the hepatocellular carcinoma treatment landscape.

Advanced HCC: Key Takeaways 

Between The Lines

 is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.

IMbrave 150: Overview

EP: 1.IMbrave 150: Overview

EP: 2.IMbrave 150: Patient Characteristics

EP: 3.IMbrave 150: Updated Outcomes

EP: 4.Using Atezolizumab + Bevacizumab in Practice

EP: 5.Vp4 and Baseline Varices Data in IMbrave 150: Clinical Implications

EP: 6.AE Management with Atezolizumab + Bevacizumab

EP: 7.CheckMate 9DW: Overview

EP: 8.Advanced HCC: Key Takeaways